News

Mural Oncology Set to Showcase Research at SITC Annual Meeting

Mural Oncology Set to Showcase Research at SITC Annual Meeting

Mural Oncology Set to Showcase Research at SITC Annual Meeting

Mural Oncology plc (NASDAQ: MURA), a pioneering company focused on immuno-oncology, is gearing up for a significant event—the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). This important gathering will take place from November 6-10, 2024, in Houston, Texas. Mural Oncology is excited to announce they will be presenting key insights into their innovative therapies aimed at addressing critical cancer treatment challenges.

Presentations Highlighting Cutting-Edge Research

At the event, Mural Oncology plans to showcase three impactful poster presentations. The first presentation will delve into pharmacodynamic data derived from the phase 1/2 ARTISTRY-3 study, which explores less frequent dosing of nemvaleukin, their engineered interleukin-2 therapy. This research is essential, as it aims to provide deeper insight into the tumor microenvironment and how treatment with nemvaleukin can be optimized.

Details of Upcoming Presentations

Here are the specific details about the presentations Mural Oncology will be sharing at the SITC:

Tumor Microenvironment Study

Title: Tumor microenvironment pharmacodynamic effect of nemvaleukin less frequent intravenous dosing in multiple solid tumors: results from the phase 1/2 ARTISTRY-3 study
Abstract Number: 217
Presentation Date: Friday, Nov. 8

IL-18 and IL-12 Research Findings

Title: Preclinical efficacy and immune activity of half-life extended IL-18 fusion proteins resistant to IL-18BP suppression
Abstract Number: 1340
Presentation Date: Saturday, Nov. 9

Title: Modulation of IL-12p70 exposure and activity following sequential administration of tumor targeted self-assembling split IL-12 subunits
Abstract Number: 1300
Presentation Date: Saturday, Nov. 9

About Mural Oncology

Mural Oncology is utilizing its advanced protein engineering platform to create innovative immunotherapies for cancer. With an emphasis on developing cytokine therapies, the company aims to provide meaningful benefits to patients facing various types of cancer. Their lead candidate, nemvaleukin, is currently involved in trials for platinum-resistant ovarian cancer and mucosal melanoma, with results expected in the near future.

The Functionality of Nemvaleukin

Nemvaleukin is engineered to enhance the anti-tumor properties of the interleukin-2 (IL-2) pathway without the side effects commonly associated with traditional treatments. It specifically interacts with the intermediate-affinity IL-2 receptor, promoting the growth of CD8+ T cells and natural killer cells, essential for mounting effective immune responses against tumors, while minimizing the unwanted expansion of regulatory T cells.

Exploring IL-18 and IL-12 Programs

Mural Oncology is also making strides in its IL-18 program, which aims to overcome limitations posed by IL-18 binding protein, a decoy receptor that hinders the efficacy of native IL-18. Through innovative protein engineering techniques, they are working to enhance the stability and potency of IL-18.

Furthermore, the IL-12 program is equally crucial. By reformulating IL-12 into separate inactive components, Mural Oncology seeks to deliver powerful anti-cancer effects while avoiding systemic toxicity. This revolutionary approach could change how IL-12 therapies are administered and ultimately improve patient outcomes.

Contact Mural Oncology for Inquiries

If you have further questions or require more information about Mural Oncology and its programs, please reach out to:

Katie Sullivan
Email: katie.sullivan@muraloncology.com

Frequently Asked Questions

What is Mural Oncology known for?

Mural Oncology is recognized for developing innovative cytokine-based immunotherapies aimed at improving cancer treatment outcomes.

What will Mural Oncology present at the SITC meeting?

The company will present data from its ARTISTRY-3 study and findings on its IL-18 and IL-12 programs.

Why is nemvaleukin significant?

Nemvaleukin is engineered to enhance immune responses against tumors while minimizing adverse side effects, representing a promising treatment option for patients.

What is the purpose of the IL-18 program?

The IL-18 program aims to enhance the efficacy and durability of IL-18, making it more effective in stimulating immune responses against cancer.

How can I learn more about Mural Oncology?

Visit Mural Oncology's official website or contact them directly for additional information on their research and development initiatives.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Intestinal Worms: New Science and Old Challenges

Updated Category News Views 48

Intestinal Worms: A Modern Twist on an Old Tale Just when you thought you'd heard it all, here comes the notion that intestinal worms might actually be good for us. The stuff of cringe-worthy junior high biology classes is now strutting its stuff in F1000Research. Sounds odd? Maybe, but there's a half-century of science behind it. Old Foes with New Friends These...

Continue Reading
PG&E Breaks Ground with Global Emergency Accreditation

Updated Category News Views 24

Pioneering Emergency Management Standards The landscape of emergency management just got a shakeup, folks. PG&E, an energy utility giant that powers the lives of over 16 million Californians, bagged a distinction that doesn’t roll around every day—indeed, the first of its caliber in the utility sector. Earning accreditation from the big dogs at the Emergency...

Continue Reading
Transforming Healthcare Leadership Through Systemic Change

Updated Category News Views 22

Reframing Physician Leadership for Systemic Transformation Here we go, diving into some serious change-making in the healthcare sphere. If you've ever wandered through a hospital corridor, you've likely felt the tension between docs and the suits. The American Association for Physician Leadership (AAPL) is stirring the pot with a fresh book that might just be the catalyst...

Continue Reading
Blue Moon Metals Scraps Major Acquisition Plan

Updated Category News Views 87

Blue Moon Metals' Acquisition Detour Blue Moon Metals Inc. (NASDAQ: BMM), a name that's been stirring up chatter for its ambitious mining ventures, has waved goodbye to its planned acquisition of 33 U.S.-based tungsten and antimony projects. This move, announced on October 30, 2026, may have caught some investors off guard. The acquisition sounded like a good fit: a...

Continue Reading
Mondel?z Bites into Undercover: Snack Market Impact

Updated Category News Views 46

Snack World Shake-Up: Mondel?z Steps In Ever find yourself browsing the snack aisle, wondering how many brands are duking it out for shelf space? Well, brace yourself, because Mondel?z International — the big cheese in the global snack game — is grabbing a sizeable bite of Undercover Snacks. This is no small news in the land of chocolate-covered and frosted quinoa...

Continue Reading
Endava's Securities Class Action Heats Up Wall Street

Updated Category News Views 13

A Head-Spinning Fall for Endava Endava's recent tumble on the NYSE has investors rubbing their eyes in disbelief. A jaw-dropping 25% slide in share value on September 22, 2026, has everyone scrambling for answers. Looks like some serious skeletons were hiding deep in Endava's closets—management snafus and fuzzy accounting being at the forefront. This debacle has peeled...

Continue Reading
Z Squared Eyes 150 MW Expansion at Arkansas Site

Updated Category News Views 48

Turning Power into Potential at Union County Next stop, Union County, Arkansas. Z Squared Inc. (Nasdaq: ZSQR) isn't just talking shop; they're getting down to work. With a freshly acquired site through Paradox Data, LLC, Z Squared's planning to turn vision into reality. The site's already armed with 8 MW of juice, all ready to roll, but their ambitions shoot up to 150 MW...

Continue Reading
Midterms and Retirement: Evaluate Precious Metals

Updated Category News Views 134

Understanding the Financial Climate Amid Midterms Here we go, folks—the red, white, and blue circus we know as the midterms is back in town. And while politicians do their song and dance, you gotta ask yourself if your investments are strong enough to weather any storm those election winds might blow your way. American Independence Gold is waving the flag, telling folks...

Continue Reading
Navigating Holiday Eating with GLP-1 Support

Updated Category News Views 49

GLP-1 Programs: A New Holiday Challenge As if the holidays weren't already a puzzle with family dinners and over-the-top office parties, folks on a GLP-1 program have another set of questions, like navigating a buffet without guilt. Ain’t no sugarcoating it—December throws every routine straight out the window. It's not just about what pie to eat, but how to keep your...

Continue Reading
Viatris Bids for Pacira: Strategic Healthcare Move

Updated Category News Views 51

Viatris Takes Strategic Step With Pacira Acquisition You ever notice how in the pharmaceutical games, it's not always the pills but the strategic moves that make the money? Viatris Inc., the global healthcare heavyweight, has just rolled the dice. They've initiated a tender offer to acquire Pacira BioSciences, a player in the non-opioid pain management market. Here's the...

Continue Reading

Top 5 Most Recently Viewed Articles

Matthews International Prepares for Q2 Fiscal 2025 Earnings Call

Updated Category News Views 340

Matthews International's Upcoming Earnings Release PITTSBURGH — Matthews International Corporation (Nasdaq: MATW) has exciting plans to unveil its financial results for the second quarter of fiscal year 2025. The earnings announcement is scheduled for Wednesday after the market closes. This is an important time for investors, as it provides insights into the company's...

Continue Reading
Investigation Launched for Proficient Auto Logistics, Inc.

Updated Category News Views 291

Overview of Proficient Auto Logistics, Inc. Proficient Auto Logistics, Inc. (NASDAQ: PAL) has come under scrutiny as Pomerantz LLP initiates an investigation into the company's financial practices. The firm is exploring whether Proficient Auto and its leadership have engaged in securities fraud or any unethical business methods. Details of the Investigation The ongoing...

Continue Reading
Abacus Global Management Sees Revenue Surge with $44.1M Q1

Updated Category News Views 124

Abacus Global Management Reports Exceptional Q1 Performance Abacus Global Management, Inc. (NASDAQ: ABL), a prominent player in the alternative asset management sector, has shared impressive financial results for the first quarter of 2025. The company's total revenue exceeded expectations as it reached $44.1 million, effectively doubling from the same quarter of the...

Continue Reading
Korro Bio's Upcoming Conferences: Innovations in RNA Editing

Updated Category News Views 242

Korro Bio's Upcoming Conferences Korro Bio, Inc. (NASDAQ: KRRO) is set to engage with investors and the wider scientific community during several upcoming conferences this September. These engagements are pivotal for displaying its advancements in RNA editing technology, a focus of the company. Citi's Biopharma Conference Dr. Ram Aiyar, the Chief Executive Officer of...

Continue Reading
Qualcomm’s Impressive Q3 Financial Results Reveal Growth

Updated Category News Views 111

Qualcomm's Strong Q3 Performance Qualcomm Inc (NASDAQ: QCOM) has showcased outstanding financial results for the third quarter, demonstrating resilience and growth in a competitive market. The company reported a revenue of $10.365 billion, reflecting a 10% increase compared to the previous year and exceeding analysts' estimates of $10.333 billion. Key Financial Highlights...

Continue Reading